UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

~~Date of Report (Date of earliest event reported): September 15~~October 21, 2025 ~~(September 8, 2025)~~

Date of Report (Date of earliest event reported)

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

Indiana	001-16751	35-2145715
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

220 Virginia ~~Avenue~~Ave

Indianapolis, IN 46204

(Address of principal executive offices) ~~(Zip~~and ~~Code~~zip code)

(833) 401-1577

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ELV NYSE


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $0.01	ELV	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act ~~of 1933~~ (§230.405 of this chapter) or Rule 12b-2 of the ~~Securities~~ Exchange Act ~~of 1934~~ (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8 2.0102 ~~Other~~- ~~Events~~Results of Operations and Financial Condition.

~~The~~On ~~Notes~~October 21, ~~Offering~~2025, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

OnNone ~~September 15,~~of ~~2025, Elevance Health, Inc. (~~the ~~“Company”)~~information ~~closed~~furnished ~~its~~in ~~sale~~this ofItem ~~$750 million~~2.02 ~~aggregate~~or ~~principal~~Exhibit ~~amount~~99.1 ofhereto ~~its~~shall ~~4.000%~~be ~~Notes~~deemed ~~due~~to ~~2028~~be ~~(the~~ “~~2028 Notes~~filed”), ~~$750 million~~for ~~aggregate~~purposes ~~principal amount~~ of ~~its 4.600% Notes due 2032 (the “2032 Notes”), $1,000~~Section ~~million~~18 ~~aggregate principal amount~~ of ~~its 5.000% Notes due 2036 (~~the ~~“2036~~Securities ~~Notes”)~~Exchange ~~and~~Act ~~$500 million aggregate principal amount~~ of ~~its 5.700% Notes due 2055 (the “2055 Notes” and~~1934, ~~together~~as ~~with~~amended. ~~the~~Unless ~~2028~~expressly ~~Notes,~~set ~~the~~forth ~~2032~~by ~~Notes~~specific ~~and~~reference ~~the~~in ~~2036~~such ~~Notes~~filings, ~~the~~none “Notes”) pursuant to an Underwriting Agreement, dated September 8, 2025 (the “Underwriting Agreement”), among the Company and BofA Securities, Inc., Deutsche Bank Securities Inc. and Mizuho Securities USA LLC, as representatives of the ~~several~~information ~~underwriters~~furnished ~~named~~in onthis ~~Exhibit~~report Ashall ~~thereto~~be ~~(the~~incorporated ~~“Underwriters”).~~by ~~The~~reference ~~Notes~~in ~~have~~any ~~been~~filing ~~registered~~ under the Securities Act of 1933, as amended ~~(the “Act”)~~, ~~pursuant~~whether tomade abefore ~~registration~~or ~~statement~~after onthe ~~Form~~date ~~S-3~~hereof ~~(File~~and ~~No. 333-275251)~~regardless ~~previously~~of ~~filed~~any ~~with~~general ~~the~~incorporation ~~Securities~~language ~~and~~in ~~Exchange~~such ~~Commission (the “SEC”) under the Act~~filings.

~~The~~Item ~~Company received proceeds of approximately $2,972~~9.~~7 million~~01 ~~from~~Financial ~~the~~Statements ~~sale of the Notes after deducting underwriting discounts~~ and ~~its offering expenses~~Exhibits. The Company intends to use the net proceeds to repay or redeem all of the $400 million aggregate principal amount of its 5.350% senior notes due 2025 and to redeem or otherwise repurchase all of the $500 million aggregate principal amount of its 4.900% senior notes due 2026, in each case at or prior to their respective maturities. The Company intends to use the remainder of net proceeds for working capital and for general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of other short-term and long-term debt, and the repurchase of the Company’s common stock pursuant to its share repurchase program. The Indenture (as defined below) does not prohibit or limit the incurrence of indebtedness and other liabilities by the Company or its subsidiaries.

The Notes have been issued pursuant to an Indenture, dated as of November 21, 2017 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”). Interest on the 2028 Notes, the 2032 Notes and the 2055 Notes is payable semi-annually in arrears on March 15 and September 15 of each year, commencing March 15, 2026. Interest on the 2036 Notes is payable semi-annually in arrears on January 15 and July 15 of each year, commencing January 15, 2026. Each interest payment on the 2028 Notes, the 2032 Notes and the 2055 Notes will be made to the persons who are registered holders of such Notes at the close of business on the immediately preceding March 1 or September 1 (whether or not a business day), as applicable. Each interest payment on the 2036 Notes will be made to the persons who are registered holders of such Notes at the close of business on the immediately preceding January 1 or July 1 (whether or not a business day), as applicable. Interest, in each case, will be computed on the basis of a 360-day year of twelve 30-day months.

The Notes may be declared immediately due and payable by the Trustee or the holders of 25% of the principal amount of the Notes of the affected series if an event of default occurs under the Indenture and has not been cured. An event of default generally means that the Company (1) fails to pay the principal or any premium on a Note on its due date, (2) does not pay interest on a Note within 30 days of its due date, (3) remains in breach of any other term of the Indenture for 90 days after its receipt of written notice of such failure or (4) files for bankruptcy or certain other events in bankruptcy, insolvency or reorganization occurs.

The 2028 Notes will mature on September 15, 2028, the 2032 Notes will mature on September 15, 2032, the 2036 Notes will mature on January 15, 2036 and the 2055 Notes will mature on September 15, 2055. Prior to (i) with respect to the 2028 Notes, August 15, 2028 (one month prior to the maturity date of such Notes), (ii) with respect to the 2032 Notes, July 15, 2032 (two months prior to the maturity date of such Notes) (iii) with respect to the 2036 Notes, October 15, 2035 (three months prior to the maturity date of such Notes), and (iv) with respect to the 2055 Notes, March 15, 2055 (six months prior to the maturity date of such Notes) (each such date, a “Par Call Date”), the Company may redeem the applicable series of Notes at its option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed discounted to the redemption date (assuming that such Notes matured on their applicable Par Call Date), on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, as defined in the Indenture, plus 10 basis points in the case of the 2028 Notes, 15 basis points in the case of the 2032 Notes, 15 basis points in the case of the 2036 Notes and 20 basis points in the case of the 2055 Notes, less (b) interest accrued to the redemption date; and (2) 100% of the principal amount of the Notes to be redeemed; plus, in either case, accrued and unpaid interest on the applicable Notes to the redemption date.

On or after the applicable Par Call Date for the respective Notes, the Company may redeem the Notes of the applicable series in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes being redeemed, plus accrued and unpaid interest thereon to such redemption date.

Unless the Company has exercised its right to redeem the Notes in full as described above, upon the occurrence of both (1) a change of control of the Company and (2) a downgrade of a series of the Notes below an investment grade rating by each of Moody’s Ratings, S&P Global Ratings and Fitch Ratings, Inc. within a specified period, the Company will be required to make an offer to purchase all of the Notes of such series at a price equal to 101% of the principal amount of such Notes, plus any accrued and unpaid interest to the date of repurchase.

Certain of the Underwriters and their affiliates are full service financial institutions that have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with the Company and its affiliates, for which they have received, or may in the future receive, customary fees and commissions.

The foregoing description of the issuance and sale does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is incorporated by reference hereto as Exhibit 1.1, and the Indenture, which was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 21, 2017 and is incorporated by reference hereto as Exhibit 4.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are being filed herewith:


Exhibit No.		Exhibit

99.1		Press Release, dated October 21, 2025, reporting Elevance Health, Inc. financial results for the quarter ended September 30, 2025.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

ExhibitNo.		Exhibit
1.1		Underwriting Agreement, dated as of September 8, 2025, among the Company and BofA Securities, Inc., Deutsche Bank Securities Inc. and Mizuho Securities USA LLC
4.1		Indenture, dated as of November 21, 2017, among the Company and the Bank of New York Mellon Trust Company, N.A. as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 21, 2017)
4.2		Form of the 4.000% Notes due 2028
4.3		Form of the 4.600% Notes due 2032
4.4		Form of the 5.000% Notes due 2036
4.5		Form of the 5.700% Notes due 2055
5.1		Opinion of Hogan Lovells US LLP
5.2		Opinion of Faegre Drinker Biddle & Reath LLP
23.1		Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1)
23.2		Consent of Faegre Drinker Biddle & Reath LLP (included in the opinion filed as Exhibit 5.2)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

~~SIGNATURES~~This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

~~Pursuant~~SIGNATURE ~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

~~Dated:~~Pursuant ~~September 15~~to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 21st day of October, 2025.

ELEVANCE HEALTH, INC. By: /s/ Kathleen S. Kiefer Name: Kathleen S. Kiefer Title: Chief Governance Officer &and Corporate Secretary

Filing Compare · Elevance Health, Inc.